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ABSTRACT
We and others have shown that the Tissue Inhibitor of Metalloproteinases-1 
(TIMP-1), a member of the inflammatory network exerting pleiotropic effects in the 
bone marrow (BM) microenvironment, regulates the survival and proliferation of 
different cell types, including normal hematopoietic progenitor cells. Moreover, TIMP-1  
has been shown to be involved in cancer progression. However, its role in leukemic 
microenvironment has not been addressed. Here, we investigated the activity of 
TIMP-1 on Acute Myelogenous Leukemia (AML) cell functions. First, we found that 
TIMP-1 levels were increased in the BM plasma of AML patients at diagnosis. In vitro, 
recombinant human (rh)TIMP-1 promoted the survival and cell cycle S-phase entry 
of AML cells. These kinetic effects were related to the downregulation of cyclin-
dependent kinase inhibitor p21. rhTIMP-1 increases CXCL12-driven migration of 
leukemic cells through PI3K signaling. Interestingly, activation of CD63 receptor 
was required for TIMP-1’s cytokine/chemokine activity. Of note, rhTIMP-1 
stimulation modulated mRNA expression of Hypoxia Inducible Factor (HIF)-1α, 
downstream of PI3K/Akt activation. We then co-cultured AML cells with normal or 
leukemic mesenchymal stromal cells (MSCs) to investigate the interaction of TIMP-1  
with cellular component(s) of BM microenvironment. Our results showed that the 
proliferation and migration of leukemic cells were greatly enhanced by rhTIMP-1 in 
presence of AML-MSCs as compared to normal MSCs. Thus, we demonstrated that 
TIMP-1 modulates leukemic blasts survival, migration and function via CD63/PI3K/
Akt/p21 signaling. As a “bad actor” in a “bad soil”, we propose TIMP-1 as a potential 
novel therapeutic target in leukemic BM microenvironment.
INTRODUCTION
Acute Myelogenous Leukemia (AML) is a clonal 
disorder which originates from a rare population of 
leukemia stem cells (LSCs) [1]. Over the last years major 
efforts have been made to improve the clinical outcome 
of AML patients; however, their overall prognosis is still 
poor especially for patients harboring unfavorable biologic 
factors at diagnosis [2, 3].
Recent reports have unveiled a pathogenetic 
link between inflammation and oncogenesis [4–7]. 
Whereas this finding is well-accepted for solid tumors, 
the relationship between inflammatory networks and 
leukemogenesis has not been fully elucidated. Nonetheless, 
recent data highlight how hematopoietic stem progenitor 
cells (HSPCs) fate is dictated by intrinsic and extrinsic 
factors and how HSPCs may actively sense danger signals 
and pro-inflammatory cytokines [8–10]. Moreover, the 
cross-talk between leukemic cells and BM stromal cells 
may create a suitable environment that promotes malignant 
transformation and disease progression. Several factors 
and pathways have been implicated and described [11, 12]. 
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Among them, the tuned regulation of the balance between 
synthesis and degradation of extra-cellular matrix (ECM) 
macromolecules by matrix metalloproteinases (MMPs) 
and their inhibitors is critical [13]. Indeed, an altered 
MMPs/Tissue Inhibitor of MetalloProteinases-1 (TIMP-1) 
expression or activity affects steady state hematopoiesis 
and results in increased cell proliferation, thus favoring 
oncogenesis, including leukemogenesis [14]. Indeed, 
TIMP-1 levels increase in response to inflammation [15]. 
Initially described as an endogenous inhibitor of MMPs 
and the membrane-bound metalloproteinase ADAM-10, 
TIMP-1 also displays cytokine-like functions, mediated 
by the engagement of a specific membrane receptor, 
namely CD63 [16]. CD63 is known as a member of 
the tetraspanins, that are a superfamily of cell surface-
associated membrane proteins involved in cell activation, 
adhesion, differentiation and tumor invasion [17]. In breast 
cancer and melanoma cells, CD63 is abundantly expressed 
and interacts with TIMP-1 at cell surface, resulting in 
activation of cell survival signaling [18, 19]. At the 
functional level, TIMP-1 exerts pleiotropic effects in the 
BM microenvironment, such as the regulation of cellular 
proliferation, apoptosis and differentiation [19–21]. In 
particular, we previously found that TIMP-1 regulates 
the function of HSPCs promoting clonogenic efficiency 
and survival of normal CD34+ cells via the activation 
of the CD63/PI3K/pAkt signaling pathway, suggesting 
that TIMP-1 may be a key player in the network of pro-
inflammatory factors modulating HSPC functions [22]. 
Similarly, in solid tumors, TIMP-1 improves the metastatic 
potential of cancer cells [23]. Interestingly, upregulated 
TIMP-1 levels are associated with unfavourable prognosis 
in several tumors including breast or colorectal cancer and 
lung carcinoma [24–26]. In hematological malignancies, 
TIMP-1 promotes differentiation of lymphoma cells, 
whereas increased TIMP-1 serum levels are associated 
with advanced myeloma [27–30].
In the present study we investigated, in vitro, the 
function and molecular pathways mediated by TIMP-1 in 
the microenvironment of AML, providing further evidence 
to support the relationship between inflammation and 
leukemia. A better definition of the mechanisms regulating 
the interplay of leukemic cells within bone marrow 
(BM) microenvironment, may have important clinical 
implications for the development of novel and effective 
therapeutical strategies. 
RESULTS
TIMP-1 is detectable in BM and PB of AML 
patients 
In normal hematopoiesis, TIMP-1 regulates the 
survival and proliferation of different cell types [15, 22]. 
However, its role in AML BM microenvironment is not 
yet clear. Therefore, we first evaluated the BM plasma 
and PB serum level of TIMP-1 in leukemic patients at 
diagnosis. We found detectable amounts of TIMP-1 both 
in BM and PB with a median concentration of 112.6 ng/ml 
(range 72.25–157.3 ng/ml) and 139.4 ng/ml (range 
84.47–273.9 ng/ml), respectively (Figure 1A-1B). In 
particular, compared with control BM samples, the 
plasma levels were increased in AML patients (p ≤ 0.05). 
These results extend previous data in other hematological 
malignancies, such as pediatric ALL [32] and suggest 
the potential functional role of TIMP-1 within AML 
microenvironment. Moreover, they indicate the optimal 
concentration of TIMP-1 for functional studies.
TIMP-1 increases the clonogenic efficiency of 
AML blasts maintaining an apoptosis-resistant 
phenotype 
In our previous work [22], we found that TIMP-1 
increases the clonogenic efficiency of normal HSPCs 
isolated from umbilical CB units. Thus, we studied the 
effects of increasing concentration of TIMP-1 (ranging 
between 10–300 ng/ml) on the clonogenic output of 14 
primary AML at diagnosis. As shown in Figure 2A, TIMP-1 
(at 100 ng/mL) significantly increased colony formation 
(CFU-L) from AML patients (p ≤ 0.01). In addition, the 
CFU-GM growth was positively enhanced by TIMP-1 
(Supplementary Figure S1, p ≤ 0.01). 
When we tested myeloid differentiation markers 
(CD38 and CD11b) or hemopoietic stem/progenitor cells 
marker (CD34) in the blasts of AML patients, we did 
not find any differences between untreated or TIMP-1 
treated AML samples (data not shown). We then 
investigated whether TIMP-1 promotes the survival of 
AML blasts. To this end, we treated leukemic cells with 
the optimal concentration of TIMP-1 (i.e. 100 ng/mL) 
and we evaluated cell viability at different time points 
by colorimetric assay (MTS assay). As summarized in 
Figure 2B, after 48 and 72 hours, the addition of TIMP-1 
significantly increased the number of viable leukemic 
blasts, as evaluated as fold-change over control sample 
(5.6- and 5.9-fold increase, respectively; p ≤ 0.001). 
Moreover, when we evaluated the apoptotic rate of 
leukemic blasts, we found that AML cells incubated for 
up to 72 hours in presence of TIMP-1 showed a significant 
decrease in their programmed cell death (Figure 2C). In 
particular, the mean percentage of apoptotic cells was 
reduced in presence of TIMP-1 as compared to control 
samples (33 ± 3.5% and 53 ± 3.14%, respectively; 
p ≤ 0.001). Overall results and data from a representative 
example (panel C) are shown in Figure 2 and from 
individual patients (Supplementary Figure S2). Taken 
together, these data demonstrate that TIMP-1 promotes the 
survival and the clonogenic activity of leukemic blasts by 
significantly reducing apoptosis.
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TIMP-1 stimulates cell cycling of leukemic 
blasts in association with p21WAF1/CIP1 
downregulation
We then studied the effect of TIMP-1 on cycling 
of AML cells. As shown in Figure 3A, after 24 hours of 
TIMP-1 incubation, we observed a reduced percentage 
of cells in G0/G1 phase (percentage of untreated G0/
G1-phase cells 86.66 ± 1.34 % vs 77 ± 3.03 % of TIMP-
1-treated cells; p ≤ 0.05). Simultaneously, we detected 
a slight, but significant, increase in the percentage of 
leukemic cells in S-phase (percentage of untreated 
S-phase cells 7.4 ± 0.77  % vs  15.5 ± 3.1% of TIMP-
1-treated cells; p ≤ 0.01). These data suggested a role of 
TIMP-1 in promoting AML cell cycle progression. In 
order to confirm this observation, we analyzed the effect 
of TIMP-1 on expression of p21WAF1/CIP1, a cell cycle 
inhibitor [33] (Figure 3B). Interestingly, the normalized 
mean fluorescence intensity (nMFI) of p21 expression 
was significantly reduced in leukemic cells after exposure 
to TIMP-1 for 24 hours as compared with untreated cells 
(nMFI: 3.1±1.1 vs 4.5±1.5, respectively; p ≤ 0.05; data not 
shown). To further confirm our results, we analysed p21 
protein reduction by western blot (Figure 3C). This assay 
confirmed the reduction of p21 protein after treatment 
with TIMP-1, whereas transcript levels were not affected 
(data not shown). These results suggest that TIMP-1 
stimulates cell-cycle progression of leukemic blasts from 
AML patients.
TIMP-1 enhances CXCL12-driven migration of 
AML blasts 
To test the effect of TIMP-1 on the migratory 
capacity of AML cells, we assessed, in vitro, the response 
of AML cells toward a CXCL12 gradient in presence 
or absence of TIMP-1. As reported in Figure 4A, the 
migration rate of AML cells, when TIMP-1 was added 
in absence of CXCL12, was not significantly higher than 
control samples. Although these results could rely, at 
least in part, on TIMP-1’s survival effects, the addition of 
TIMP-1, in presence of CXCL12, increased the migration 
rate of leukemic cells over that observed with medium 
(spontaneous migration) and CXCL12 alone (p ≤ 0.0001 
and p ≤ 0.01, respectively). Conversely, when TIMP-1 was 
added to CXCL12 as chemo-attractant, the migration of 
AML cells was not significantly increased. No differences 
in spontaneous or CXCL12-induced migration were 
observed when PB or BM cells were compared (data not 
shown). However, migration of TIMP-1 treated PB cells 
toward CXCL12 gradient was slightly higher than the 
migration of the BM cells (PB vs BM, 57.14% ± 5.5% vs 
46.09% ± 7.7%, respectively; p=ns). To further support 
this finding, we investigated the migratory response 
of AML cells after pre-incubation with AMD3465, a 
potent and selective CXCR4 antagonist and anti-TIMP-1 
neutralizing Ab. After incubation with AMD3465, the 
migration of leukemic blasts was inhibited and the effect 
of CXCL12 was comparable to medium alone (Figure 4B). 
Importantly, pre-incubation with the CXCR4 inhibitor 
completely abrogated the effect of TIMP-1 treatment 
toward CXCL12-gradient (p ≤ 0.001). Also, anti-TIMP -1 
neutralizing Ab reversed the effects of TIMP-1 on 
migratory response of AML cells. 
CD63 is required for TIMP-1-mediated effects 
on AML blasts
To elucidate the molecular pathway ignited by 
TIMP-1 and its cytokine-like activity in leukemic blasts, 
we first investigated the expression and the functionality of 
CD63, which is known to mediate TIMP-1 effect [16]. The 
Figure 1: The plasma levels of TIMP-1 are increased in AML patients. TIMP-1 levels were measured by ELISA in in plasma 
and serum of AML patients and control samples. (A) BM plasma concentrations of TIMP-1 were compared between AML patients at 
diagnosis (n = 6) and control samples (*p < 0.05). (B) In addition, PB serum concentrations of TIMP-1 were quantified in patients (n = 12) 
and compared to control samples.
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mean percentage of CD63-positive blasts from the total of 
AML patients was 60.83% ± 5.485% (range, 26.40–93.40). 
In particular, the mean percentage was 64.05% ± 8.024% 
(range, 32.1–93.4) in PB samples and 56.53% ± 7.476% 
(range, 26.4–79.6) in BM samples. Of note, we did not find 
any significant correlation between patient characteristics 
and CD63 expression or different functions mediated by 
TIMP-1 (data not shown). Interestingly, migrated leukemic 
blasts toward CXCL12 plus TIMP-1 had a significantly 
increased expression of CD63 as compared to the cells 
migrated toward CXCL12 alone (p ≤ 0.05) (Figure 5A). 
We then, sorted CD63 positive and negative leukemic 
blasts and tested their ability to respond to TIMP-1 in 
migration assay. Noteworthy, only the migratory capacity 
of CD63+ fraction appeared significantly promoted 
(p ≤ 0.05; Figure 5B), while the proportion of migrating 
Figure 2: Clonogenic output and survival of leukemic blasts is positively enhanced by exposition to TIMP-1. Circulating 
leukemic blasts were isolated from AML patients (n = 12) and cultured in semisolid medium in the presence of TIMP-1. After 14 days, 
the total CFU-L output was assessed as above described. (A) The clonogenic output of the AML-derived leukemic cells was significantly 
stimulated by TIMP-1 (100 ng/ml, **p ≤ 0.01). No other concentration of TIMP-1 were effective. The results are expressed as growth fold 
change versus untreated control samples. The mean number of colonies in untreated (0 ng/ml) and treated (100 ng/ml) AML samples was 
18.8 ± 5.8 vs 30.2 ± 9.2, respectively. Specifically, only 2 patients (PT #6 and #13 in the Table patients) were not responsive to TIMP-1 
treatment in CFU-L assay. Data are presented as mean ± SEM of 12 patients, the error bars are the mean of each duplicate. Survival 
of leukemic blasts from AML patients is positively enhanced by TIMP-1. (B) AML blasts were cultured for 24-48-72 hrs in the presence 
of TIMP-1 (48–72 hrs, ***p ≤ 0.001; n = 3). Survival rate is evaluated by cell titer assay and expressed as fold-change taking the value of 
untreated cells at each time point as 1. (C) AML cells from 14 patients were in vitro treated for 2 days with TIMP-1 and the percentage of 
cell viability was assessed after AnnexinV/PI staining, as described in methods. Representative dot-plots showing the percentage of live, 
apoptotic and necrotic cells in leukemic blasts as determined by flow cytometry. Mean of percentage in apoptotic cell (Annexin V positive and 
both Annexin V/ PI positive cells) in the presence or absence of TIMP-1 (***p ≤ 0.001). The mean percentage of apoptotic cells (Annexin V 
positive and both Annexin V/ PI positive cells) was 53.0 ± 3.1% (range: 34.5–74.6) for control and 33.0 ± 3.5% (range: 15.4–53.0) for TIMP-1 
treated cells. Data are presented as mean ± SEM.
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CD63– AML cells in presence of TIMP-1 cells was 
comparable to that migrated with CXCL12-gradient alone. 
Overall, these findings support the hypothesis that TIMP-1 
modulates the CXCL12-mediated migration through the 
interaction with the CD63 receptor, exerting cytokine-like 
function in leukemic blasts.
TIMP-1 induced PI3K/Akt and HIF-1α signaling 
pathway in leukemic blasts
We then investigated the signaling pathway activated 
by TIMP-1 exposure. We previously demonstrated that in 
normal CD34+ cells PI3K/Akt is the main signaling pathway 
induced by TIMP-1 [22]. Based on these results, we tested 
TIMP-1 effects on AML cell function in presence of the 
PI3K-inhibitor LY294002. Pre-incubation of AML cells 
with LY294002 plus TIMP-1 significantly decreased their 
clonogenic output as compared to TIMP-1 alone (p ≤ 0.05) 
(Figure 6A), reverted TIMP-1-mediated anti-apoptotic 
activity (p ≤ 0.0001) (Figure 6B) and its migratory capacity 
on AML cells (Figure 6C) (p ≤ 0.0001). These results 
suggest that, similarly to normal HSC, in leukemic blasts 
the pathway of PI3K/Akt may be involved in the signaling 
induced by TIMP-1. To further support this hypothesis, we 
examined the activation/phosphorylation of Akt in TIMP-
1-treated AML cells. We firstly observed that the addition 
of TIMP-1 resulted in pAkt-Thr308 phosphorylation of 
CD63+, but not CD63–, AML cells (Figure 6D), confirming 
that CD63 binding may be important to pAkt activation by 
TIMP-1. Next, we assessed by flow cytometry the levels 
of Akt phosphorylation in leukemic blasts after exposure 
to TIMP-1. As indicated in Figure 6E, the mean value of 
nMFI of phospho-Akt was 3.5 ± 0.32 in untreated cells vs 
4.8 ± 0.7 after TIMP-1 treatment (p ≤ 0.05). Moreover, we 
determined the levels of pAkt upon TIMP-1 treatment in 
AML cells by Western blotting (Supplementary Figure S3). 
As expected, after PI3K inhibition the treatment with 
TIMP-1 had no effect on Akt phosphorylation. Finally, we 
examined the effect of TIMP-1 on the expression of HIF-1α, 
described as a downstream pathway following PI3K/Akt 
activation [34]. Of note, the expression of HIF-1α mRNA 
in leukemic blasts was found to be modulated by TIMP-1 
stimulation. Specifically, after 24 hours in presence of 
TIMP-1, a significant increase in the expression of HIF-1α 
was observed (p ≤ 0.05; Supplementary Figure S4). 
Together, these data support the hypothesis that TIMP-1 
modulates the function of leukemic blasts via PI3K/Akt 
and HIF-1α axis.
Figure 3: TIMP-1 promotes cell cycle of leukemic blasts. (A) Results are expressed as the percentage of cells in different phases 
of the cell cycle. TIMP-1 promote cell cycling of leukemic blasts cells from AML patients (phase G1 *p ≤ 0.05 and phase S **p ≤ 0,01; 
n = 9). Their distribution in the different phases of cell cycle was assessed by PI staining after 24 hrs. Data are presented as mean ± SEM. 
(B) Representative histogram of p21WAF1/CIP1 of leukemic blasts after exposure to TIMP-1 for 24 hrs. The downregulation of cyclin-
dependent kinase inhibitor p21WAF1/CIP1, which promotes cell cycle progression, were measured by flow cytometry as MFI, and is shown 
only in the presence of TIMP-1 (MFI: 2275 ± 524 TIMP-1 treated cells vs 3110 ± 223,1 untreated cells; n = 12). Specifically, only 2 patients 
(PT #11 and #15 in the Table patients) were not responsive to TIMP-1 treatment in p21 downregulation. (C) AML cells were incubated with 
TIMP-1 for 24 hrs and the relative level of p21 protein was determined by western blotting (n = 2). Representative western blot of one AML 
patient. β-actin was used as a loading control. 
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The leukemic BM microenvironment enhances 
the effects of TIMP-1 on migration of leukemic 
blasts
It is known that migration of AML cells is regulated 
by stromal cells, such as MSCs, producing CXCL12 
[35, 36]. To further investigate the role of TIMP-1 within 
BM microenvironment of AML patients, we tested the 
migratory ability of leukemic blasts after co-cultures 
with normal or leukemic MSCs in presence or absence of 
TIMP-1. No significant biological difference was found 
between normal and AML-MSCs in terms of phenotype 
and differentiation capacity (data not shown). As shown 
in Figure 7A, the CXCL12-driven migration of leukemic 
Figure 5: TIMP-1’s effects on migration are mediated by the CD63 tetraspanin receptor. (A) AML cells were seeded 
in the upper compartment of a chamber transwell migration assay ±TIMP-1 (100 ng/ml). After 24 hrs migrated AML-derived leukemic 
blasts toward CXCL12 gradient after pre-treatment with TIMP-1 show increased expression of TIMP-1 receptor (CD63) as compared 
with untreated cells. Results are expressed as normalized Mean Fluorescence Intensity (nMFI). (*p ≤ 0.05; n = 10). (B) Based on CD63 
expression, leukemic blasts were sorted in two separate fractions, CD63– and CD63+, and their capability to respond to TIMP-1 stimulation 
was assessed by migration assay. AML cell fractioning were seeded in the upper compartment of a chamber Transwell migration assay 
± TIMP-1 (100 ng/ml) toward CXCL12 (*p ≤ 0.05; n = 3). The mean number of migrated CD63+ cells was 705 ± 46 for spontaneous 
migration, 2213 ± 287 for migration toward CXCL12 gradient, 3720 ± 600 in the presence of TIMP-1 toward CXCL12 gradient. The mean 
number of migrated CD63–cells was 805 ± 52 for spontaneous migration, 2695 ± 555 for migration toward CXCL12 gradient, 2575 ± 370 
in the presence of TIMP-1 toward CXCL12 gradient. Data are presented as mean ± SEM.
Figure 4: Pre-treatment with TIMP-1 significantly promotes migration of AML cells. (A) AML cells were seeded in the 
upper compartment of a chamber Transwell migration assay ± TIMP-1 (100 ng/ml) (n = 18). TIMP-1 was added to the bottom compartment 
with or without CXCL12 (100 ng/ml), whereas was used alone in the top compartment. After over-night at 37°C, cells in the bottom 
compartments were counted and percentage of migrated cells calculated. (**p ≤ 0.01; ****p ≤ 0.0001; n = 18). The mean number of 
migrated cells was 13031 ± 2161 for spontaneous migration, 15410 ± 2367 for migration toward CXCL12 gradient, 23581 ± 3204 in 
the presence of TIMP-1 toward CXCL12 gradient and 22070 ± 4050 in the presence of TIMP-1 and CXCL12 as chemo-attractants. (B) 
Migrated AML-derived leukemic blasts toward CXCL12 gradient after pre-treatment with AMD3465 (CXCR4 antagonist) for 30 min 
± TIMP-1 (n = 9) or anti-TIMP-1 neutralizing Ab (5 µg/ml; n = 3) to evaluate the effects on migratory rate (*p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001).  Data are presented as mean ± SEM.
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blasts was not affected by TIMP-1 pre-incubation in co-
cultures with normal MSCs. Conversely, when leukemic 
blasts were co-cultured with AML-MSCs, the addition of 
TIMP-1 resulted in increased migration rate as compared 
to that observed in presence of normal MSCs (p ≤ 0.01). 
Interestingly, when we analyzed the levels of TIMP-
1 in the supernatants of co-cultures of AML cells with 
leukemic or normal MSCs, we found that TIMP-1 level 
Figure 6: TIMP-1 effects in AML cells are mediated by PI3K/Akt and HIF-1α signaling axis. (A) AML cells were cultured 
in the presence or absence of TIMP-1 (100 ng/mL) after pre-treatment with LY294002 (20 μM) and the correspondent clonogenic output 
was assessed after 14 days of culture (*p ≤ 0.05; **p ≤ 0.01; n = 3). The mean number of CFU-L was 19.7 ± 5.6, 30.3 ± 9.6 and 14.0 ± 6.2 
for control, TIMP-1-treated and LY294002-pre-treated AML cells, respectively. The results are expressed as growth fold-change versus 
untreated control samples. (B–C) In the same culture condition we tested apoptosis after 24 hrs (n = 8) and migratory behaviour toward 
CXCL12 gradient (**p ≤ 0.01; ****p ≤ 0.0001; n = 8). The mean numbers of migrated cells were 9032 ± 2970, 16432 ± 3881 and 
8450 ± 1638 for control, TIMP-1-treated and LY294002-pre-treated AML cells, respectively. The results are expressed as fold-change 
versus untreated control samples and as mean of migrated cells, respectively. (D) Representative panel of pAkt levels in TIMP-1-treated 
versus untreated cells of CD63– leukemic blasts (left panel) or CD63+ leukemic blasts (right) (n = 3). (E) Level of Akt phosphorylation 
(Thr308) in total AML cells exposed for 15 minutes to TIMP-1 (100 ng/mL) or after pre-treated with LY294002, as assessed by flow 
cytometry. Results are expressed as normalized MFI: 3.5 ± 0.32 (MFI 1387 ± 264) untreated cells vs 4.8 ± 0.7 (MFI 1524 ± 274) TIMP-1 
treated cells (*p ≤ 0.05; n = 13). Specifically, only 3 patients (PT #4-#7-#8 in the Table patients) were not responsive to TIMP-1 treatment 
in pAkt activation (*p ≤ 0.05; n = 13). 
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was higher in presence of HD-MSCs over AML-MSCs 
(263 ± 19.68 ng/ml and 162 ± 24.43 ng/ml, respectively; 
p ≤ 0.05; Figure 7B). 
TIMP-1 enhances leukemic cell survival and 
proliferation in presence of leukemic MSCs
Recently, several studies have demonstrated the 
essential role of BM stromal-derived factors in regulation 
AML cell proliferation, thus conferring chemo-resistance 
to leukemic cells [2, 11]. To test the differential effect 
of TIMP-1 on AML cell survival in presence of normal 
versus leukemic MSCs, co-cultures were set up in the 
presence or absence of TIMP-1. As shown in Figure 
8A, the survival of leukemic blasts was not affected by 
TIMP-1 in co-cultures with normal MSCs. However, 
TIMP-1 showed a slight reduction in apoptotic rate in co-
culture with AML-MSC (p ≤ 0.05). Moreover, AML cell 
proliferation was evaluated with normal MSCs or AML-
MSCs in the presence or absence of TIMP-1 plus growth 
factors, thus mimicking the BM microenvironment. When 
AML cells were co-cultured with normal MSCs, cell 
proliferation was not significantly modified after exposure 
to TIMP-1. By contrast, in co-cultures with AML-MSCs, 
the combination of TIMP-1 plus growth factors resulted 
in highly significant increase of the proliferation index as 
compared with blasts co-cultured with growth factors alone 
(p ≤ 0.01; Figure 8B–8C). In addition, a non-significant 
trend to increased cell proliferation was found from CD63-
positive fractions in AML cells (data not shown). 
Taken together, the results reported in Figures 7 
and 8 support the notion that leukemic microenvironment 
is deeply dysregulated in AML and TIMP-1 may 
preferentially exert its effects on leukemic cells in 
presence of leukemia-derived MSCs. 
DISCUSSION
Here we demonstrate that TIMP-1 increases the 
clonogenic efficiency, the survival and the migratory 
capacity of AML blasts by binding to CD63 receptor 
which, in turn, results in the activation of PI3K, Akt 
phosphorylation and regulation of downstream targets, 
such as p21 and HIF-1α. Moreover, we showed the 
potential role of TIMP-1 in the interplay between 
leukemic blasts and AML MSCs. Together, these findings 
suggest that TIMP-1 displays cytokine-like features in 
the BM microenvironment of AML patients, suggesting 
a link between the inflammatory microenvironment and 
leukemogenesis. 
Several papers report that the activation of PI3K/
Akt signaling is associated with poor outcome in 
hematological malignancies and this pathway is crucial to 
cancer cell survival and growth [37]. Here we demonstrate 
that, similarly to CB-derived CD34+ [22], binding of 
TIMP-1 to CD63 receptor is instrumental for modulation 
of AML cell functions. Whereas the role of CD63 in 
regulating cancer cell functions, such as cell activation, 
adhesion, differentiation and migration, is well-established 
in solid tumors [16, 19], its role remain unclear as for 
hematological disease. Schubert et al. [38] showed higher 
CD63 expression in AML-long-term surviving capacity 
(LTSC) growth in NOD/SCID mice, hinting the potential 
role in cell adhesion and motility. In the present paper 
Figure 7: TIMP-1’s effects on BM microenvironment: TIMP-1 significantly promotes migration of AML-derived 
leukemic cells after co-culture with AML MSCs. AML cells were co-cultured with normal (n = 2) or leukemic MSCs (n = 3) for 
3 days ± TIMP-1 (100 ng/ml). After co-culture, AML cells were collected, counted and seeded in the upper compartment of a chamber 
Transwell migration assay toward CXCL12-gradient (100 ng/ml). (A) The addition of TIMP-1 for 3 days in the presence of leukemic MSCs 
affects the migratory behaviour of AML-derived blasts cells toward CXCL12 alone (**p ≤ 0.01) (n = 6). The mean numbers of migrated 
cells were 7784 ± 2794 for spontaneous migration, 7315 ± 1776 for migration CXCL12-driven and 17732 ± 6735 for migration CXCL12-
driven after TIMP-1 treatment after co-cultures with AML-MSCs. On the contrary the mean numbers of migrated cells were 2730 ± 770 for 
spontaneous migration, 6223 ± 1811 for migration CXCL12-driven and 5613 ± 1167 for migration CXCL12-driven after TIMP-1 treatment 
after co-cultures with HD-MSCs. (B) Leukemic cells were co-cultured in presence of a normal or leukemic stroma layer. After 3 days of 
co-culture, supernatants were collected and analysed for TIMP-1 level using ELISA (*p < 0.05; n = 3). Data are mean ± SEM. “HD” means 
healthy donor. 
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we demonstrate that about half of leukemic blasts are 
CD63 positive. At the functional level, binding to CD63 is 
required for TIMP-1-mediated main effects on AML blasts 
along the PI3K/Akt pathway, as previously observed in CB 
CD34+ cells. In addition, we found that TIMP-1 stimulates 
the cell-cycle progression of leukemic blasts with a 
subsequent down-regulation of the cell-cycle inhibitor 
p21. Similarly to other pro-inflammatory cytokines 
(e.g. IFN-γ and IL-4), TIMP-1 was shown to be an inducer 
of HIF-1α expression in a liver metastasis model [39]. 
Moreover, HIF-1α mRNA and protein are overexpressed 
in human cancer and leukemic stem cells [40–41]. Our 
data suggest, for the first time, that upregulation of HIF-1α 
mRNA may be mediated by TIMP-1 in AML.
Leukemic blasts have been shown to have higher 
levels of TIMP-1 transcripts and increased TIMP-1 
expression was also observed in Non-Hodgkin 
lymphomas and Burkitt B-cell lymphoma cell lines 
Figure 8: TIMP-1’s effects on BM microenvironment: TIMP-1 promotes cell survival and proliferation in AML-derived 
blasts in the presence of AML-MSCs. (A) AML cells were co-cultured with normal (n = 2) or leukemic MSCs (n = 3) for 3 days 
± TIMP-1 (100 ng/ml) to test survival of leukemic cells (*p < 0.05; n = 4). (B) AML cells were co-cultured with normal or leukemic 
MSCs for 5 days with growth factors ± TIMP-1 (100 ng/ml). Proliferation index of CFSE-labeled leukemic blasts was calculated. Cells 
maintained in culture in the presence of medium alone was evaluated as 1 of proliferation index. AML MSCs displayed, at culture 
day 5, a significantly increased proliferation index, as compared to leukemic cells co-coltured with normal MSCs (**p ≤ 0.01; n = 12). 
(C) Representative dot-plots showing the percentage of proliferative cells gated with reduced CFSE content by flow cytometry. Left panels, 
AML cells were co-cultured with normal (on the top) or leukemic MSCs (on the bottom) for 5 days with growth factors only. Right panels, 
AML cells were co-cultured with normal (on the top) or leukemic MSCs (on the bottom) for 5 days with growth factors ± TIMP-1. Data 
are mean ± SEM. GF, growth factors.
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[28–30]. Accordingly [32], in the present work we found 
that the BM plasma levels of TIMP-1 are detectable in 
AML patients. At variance from normal CB-derived 
CD34+ cells, where TIMP-1 was shown to affect only the 
clonogenic potential, in AML TIMP-1 exerts additional 
effects, such as improving cell survival and CXCL12-
mediated migration. In the leukemic microenvironment, 
CXCL12 is secreted both by BM stromal and AML cells 
and critically modulates cell survival and retention of 
LSCs within BM [43, 44]. Our demonstration that TIMP-1 
pre-treatment of leukemic blasts promotes their migration 
towards CXCL12 support the finding of high levels of 
TIMP-1 in the BM of AML patients, suggesting a role 
for this molecule in promoting the migration of leukemic 
blasts and their dissemination in extramedullary site.
The dynamic interplay between leukemic cells and 
stromal cells is a crucial aspect of AML [45]. It is clear 
that leukemic cells alter their BM microenvironment to 
support leukemic hematopoiesis while disrupting normal 
HSC homeostasis [46]. This interaction via cytokines, 
chemokines and adhesion molecules is responsible for 
reduced chemo-sensitivity of leukemic sub-clones [47]. 
By contrast, the potential role of TIMP-1 in the interaction 
of leukemic cells with BM stromal cells is mostly 
unknown. Of note, previous investigations demonstrated 
that among 23 cytokines differentially expressed, at the 
molecular level, between normal and leukemic BM, only 
TIMP-1 was confirmed at the protein level suggesting a 
role in leukemia initiation and progression [32]. Moreover, 
the crosstalk between the matrix metalloproteinases 
system and chemokines network may modulate different 
regulators of cytokine release by primary human AML 
cells (e.g. NF-kB) [14]. In this view, our functional data 
support a role of TIMP-1 as an adverse factor within 
leukemic microenvironment. Interestingly, TIMP-1 has 
been shown to preferentially increase AML blasts survival, 
proliferation and migration in presence of AML-MSCs. 
Such discrepancy in comparison to normal MSCs is far to 
be completely elucidated. A possible explanation is that 
secreted TIMP-1 from normal MSCs saturate potential 
TIMP-1 receptors, reverting and masking the pro-survival 
and pro-migratory effects of exogenous TIMP-1. Indeed, 
previous studies demonstrated the different production 
of TIMP-1 by normal human MSCs (hMSCs), AML 
long-term marrow cultures (LTMC) and leukemic BM 
[32, 48, 49]. Although limitation of the present study is 
the small sample size of patients, our findings point to 
an abnormal interplay between leukemic cells and their 
microenvironment and suggest that AML stroma may be a 
novel target to prevent the development of leukemia. 
In conclusion, according to the “bad seeds in bad soil” 
concept [50], our data provide new evidence for TIMP-1 as a 
‘bad’ linker between inflammation and leukemogenesis. Our 
preclinical results may provide the biological background 
for further investigating TIMP-1 as a potential therapeutic 
target in the context of leukemic microenvironment.
MATERIALS AND METHODS 
Primary samples
Peripheral blood (PB, n = 9) and bone marrow 
(BM, n = 9) samples were obtained from AML patients 
(n = 18) at diagnosis after informed consent was signed. 
The percentage of AML blasts was always > 90%. Patient 
characteristics are summarized in Supplementary Table S1. 
As control samples, buffy-coats from blood transfusion 
processing and BM samples from patients with lymphomas, 
undergoing staging, with no sign of BM involvement were 
used. Control samples were rendered anonymous and not 
referred to individuals. Mononuclear cells (MNCs) were 
separated by stratification on Lympholyte-H 1.077 g/cm3 
gradient (Gibco-Invitrogen, Milan, Italy), followed 
by red blood cell lysis for 15 min at 4°C. Briefly, AML 
blasts were cultured in RPMI 1640 (Thermo Fisher 
Scientific,Waltham, MA), supplemented with 10% fetal 
calf serum (Thermo Fisher Scientific, Waltham, MA). 
Mesenchymal stromal cells (MSCs) were obtained from 
BM of healthy donors (n = 2) or AML patients (n = 3) as 
previously described [31]. MSCs were cultered at a density 
of 5,000 to 10,000 cell/cm2 in DMEM (Lonza, Veriers, 
Belgium) supplemented with 10% FBS. The isolated MSCs 
at passage 3 were evaluated by flow cytometric analysis 
for immunophenotype and were used for co-culture 
experiments (passage 3 to 5) after irradiation (10,000 Gy). 
Measurement of TIMP-1 levels
Serum was obtained from PB and plasma from 
BM samples of AML patients at diagnosis and stored at 
−80°C. The concentration of TIMP-1 in the supernatants 
from primary AML cells co-cultured with MSCs and the 
serum/plasma samples have been analysed by an ELISA 
assay (Boster Biological Technology Co., Pleasanton, CA) 
according to manufacturing instruction.
Colony-forming unit (CFU) assays
AML cells were cultured in methylcellulose medium 
(human StemMACS HSC-CFU lite w/ Epo, Miltenyi 
Biotech, Germany) at 1–5 × 105cells/mL in 35-mm Petri 
dishes in the presence or absence of TIMP-1 (10–300 ng/mL, 
Thermo Scientific, Pierce Biotechnology, Rockford, IL, 
USA). Cell cultures were maintained at 37°C in a fully 
humidified atmosphere with 5% CO2 and after 14 days 
CFU-Ls were scored. The experiments were performed 
in duplicates plates and a colony was considered to be an 
aggregate of 20 and more cells.
Apoptosis assay
AML cells were cultured in the presence of TIMP-1 
(100 ng/mL) and the apoptotic rate was evaluated at different 
Oncotarget2271www.impactjournals.com/oncotarget
time points by AnnexinV/Propidium Iodide Staining 
(Annexin-V-FLUOS-kit,Roche, Penzberg, Germany). 
Sample acquisition and analysis was performed on a BD 
Accuri C6 flow cytometer (BD Biosciences). Where 
indicated, cells were cultured in the presence of LY294002 
(PI3K inhibitor). Cell viability was also measured by 
CellTiter 96 Aqueous One Solution (Promega). AML cells 
were cultured in presence of TIMP-1 (100 ng/mL) for 
24–48 hours and cell cycle distribution were evaluated at 
different time points. Treated cells were first permeabilized 
with NP-40 (15 min at RT) and then labelled with propidium 
iodide (PI)/RNAse staining kit (BD Bioscience) (15 min at 
RT, in the dark). The DNA content was assessed by BD 
AccuriTMC6 (BD Bioscience) and results were analyzed by 
FCS express 4 software.
Cell sorting and flow cytometry
Flow cytometry studies were performed as 
previously described [22]. Leukemic blasts were labelled 
with an anti-CD63 antibody phycoerythrin (PE)-conjugated 
(eBioscience, San Diego, CA) and sorted on a FACS Aria 
(Becton Dickinson, BD Bioscience, San Jose, CA).
 Sorting gates were carefully drawn in order to avoid 
any cross-contamination among the two populations. 
Purity checks by flow cytometry was performed on each 
isolated cell population and the mean purity was 90% ± 
5%.
Phospho-Akt intracellular staining was performed 
as previously described [22]. Leukemic blasts were 
treated with TIMP-1 (100 ng/ml) for 3.5–15 min at 37°C, 
5% CO2. After fixation in 4% paraformaldehyde (PFA) in 
PBS/permeabilization, cells were washed with phosphate-
buffered saline (PBS), 0.1% bovine serum albumin (BSA) 
and incubated with pAkt (Thr308) (C31E5E) Rabbit 
monoclonal antibody (PE-conjugate; Cell Signaling) for 
30 min at room temperature (RT) in the dark. Data were 
analyzed using FCS express 4 Flow Cytometry analysis 
software (De Novo Software, Glendale, CA, USA).
For intracellular analysis of p21 protein, leukemic 
blasts were treated with TIMP-1 (100 ng/ml) for 24 hours 
at 37°C, 5% CO2.  After fixation in 4% PFA, 0.1% Saponin 
was used to permeabilize the cells.  As above cells were 
incubated with p21 antibody or negative control antibody 
and analysed by flow cytometry.
Where indicated, cells were cultured in the presence 
of 20 μM PI3K inhibitor (LY294002) (Sigma-Aldrich,Saint 
Louis, MO, USA) or 5 μM CXCR4 antagonist (AMD3465) 
for 30 minutes (Abcam, Cambridge, UK), followed by 
exposure to TIMP-1 (100 ng/ml). In selected experiments, 
cells were cultured in the presence of anti-TIMP1 antibody 
(5 µg/ml) (ab77847, Abcam, Cambridge, UK).
Negative controls were isotype-matched irrelevant 
MoAbs from BD Pharmingen or eBioscience and were 
used for setting limits of nonspecific immunoglobulin cell 
binding. Specifically, the following MoAbs were used: APC 
or PE Mouse IgG1, κ Isotype Control (Clone MOPC-21) 
and PE-Cyanine7 or FITC IgG1, k Isotype Control (Clone 
P3.6.2.8.1).
In order to normalize our data for p21 and pAkt 
staining, we calculated the normalized MFI (nMFI), as MFI 
of the stained sample/MFI of the negative control sample.
CFSE labelling and analysis
Leukemic proliferation was monitored by flow 
cytometry, monitoring Green fluorochrome carboxyl 
fluorescein diacetate succinimidyl ester (CFSE, Molecular 
Probes Europe, Leiden). AML cells were labelled with 
CFSE (5 µM) for 4 min at RT in PBS, 0.1% BSA, 
followed by the addition of ice-cold RPMI with 10% FBS 
to prevent further dye uptake. Cells were washed 3 times 
in ice-cold medium and maintained in culture for 5 days in 
RPMI with 10% FBS, with or without TIMP-1 (100 ng/ml) 
supplemented with growth factors (GF): stem cell 
factor (SCF; 50 ng/mL, Amgen, Thousand Oaks, CA), 
interleukin (IL)-3 (50 ng/mL, Miltenyi Biotech, BO, 
Italy), granulocyte macrophage colony-stimulating factor 
(GM-CSF; 10 ng/ml, Peprotech, London, UK). Data were 
analyzed by FCS express 4 Flow Cytometry analysis 
software.
Migration assay
Migration of leukemic blasts was assayed 
towards a CXCL12 gradient (100 ng/mL, Meridian 
Life Science,Memphis, TN) in trans-well chambers 
(diameter 6.5 mm, pore size 8 µm; Costar; Corning, 
New York, USA). Briefly, 50 µl of RPMI 1640 plus 10% 
FBS containing 0,5x105 cells pre-incubated or not with 
TIMP-1 were added to the upper chamber and 150 µl of 
medium ± CXCL12 were added to the bottom chamber. 
After overnight incubation at 37°C in 5% humidified 
CO2 atmosphere, inserts (upper chambers) were removed 
and transmigrated cells were counted by Trypan Blue 
exclusion test in a Neubauer chamber. The amount of 
migrated cells was expressed as a percentage of the 
input, applying the following formula: (number of cells 
recovered from the lower compartment/total number of 
cells loaded in the upper compartment) × 100%. 
Co-culture experiments
AML cells were cultured with MSCs at ratio 1:10 
in a direct cell-to-cell contact co-cultures. After 3 days in 
presence or absence of TIMP-1 (100 ng/ml) the migratory 
behaviour of leukemic blasts was assessed by migration 
assay toward CXCL12 gradient. After 5 days with SCF 
(50 ng/mL), IL-3 (50 ng/mL), GM-CSF (10 ng/ml) 
± TIMP-1 proliferation was evaluated by flow cytometry, 
monitoring CFSE labelling. After separation, MSC 
monolayers were examined by microscopy to confirm 
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that the monolayer was not damaged. To verify lack of 
significant contamination in collected AML cells, the 
expression of CD45 was measured.
Western blot analysis
AML cells were collected by centrifugation, washed 
with PBS 1% Phenylmethanesulfonyl fluoride PMSF 
(Sigma-Aldrich) and total protein extracts were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis, 
transferred onto nitrocellulose membrane (GE Healthcare, 
Buckinghamshire, UK), and then subjected to Western 
blotting. Membranes were saturated for 1 hour at room 
temperature in blocking buffer (1X tris-buffered saline, 
5 M NaCl, 20 mM Tris-HCl; pH 8.0, 0.1% Tween-20, 4% 
BSA) and then incubated overnight at 4°C with the specific 
primary antibodies: rabbit anti-pAkt Thr308 [1:3000] 
(18F.H11; Abcam) or p21 [1:1000] (#2947, Cell Signaling) 
in 4% BSA in TTBS (TBS 0,1% Tween-20) for 15–20 h 
at 4°C. Membranes were washed three times for 5 min in 
TTBS and secondary antibodies (donkey anti-rabbit HRP 
(sc-2313), donkey anti-mouse HRP (sc-2314) [1:40000] 
(Santa Cruz Biotecnology) were added for 1h at room 
temperature, and then membrane-bound were washed 
three times for 5 min in TTBS as described previously. 
Signal intensities in single blots were measured by means 
of ChemiDoc-It instrument equipped with a dedicated 
software (Launch VIsionWorksLS, Euroclone). Protein 
expression was quantified by band densitometric analysis 
using IMAGEJ 1.44p Launcher software (National 
Institutes of Health, Bethesda, MD, USA).
RNA extraction and real-time polymerase chain 
reaction (Real-Time PCR) analysis
Total RNA was isolated from treated cells using 
RNAeasy Micro Plus Kit (Qiagen, MI, Italy). First-strand 
synthesis was performed with Improm2 (Promega,Madison, 
WI) and Real Time PCR was performed with Taqman 
probe sets (Applied Biosystems,Foster City, CA) on a 
ABI Prism 7700 Sequence Detector for 40 cycles. Primer 
sequence used for HIF-1α or p21. A human internal control 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
included in every reaction for normalization and expression 
was measured for each assay relative to the GAPDH 
internal standard (ΔCt). The fold change was calculated 
from the formula 2ΔΔCt.
Statistical analysis
The results are expressed as the mean ± SEM. 
Differences between groups were compared by using 
either a Student’s t-test or ANOVA (GraphPad software, 
La Jolla, CA). P values ≤ 0.05 were considered statistically 
significant.
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